<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3517">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681859</url>
  </required_header>
  <id_info>
    <org_study_id>BME-BUET-003</org_study_id>
    <nct_id>NCT04681859</nct_id>
  </id_info>
  <brief_title>Evaluation of a Low-cost CPAP Device on Hospitalized COVID-19 Patients</brief_title>
  <acronym>OxyJet-CPAP</acronym>
  <official_title>Safety and Efficacy Evaluation of a Low-cost CPAP Device for Hypoxemic COVID-19 Patients: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangladesh University of Engineering and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dhaka Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bangladesh University of Engineering and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the preliminary safety and performance of a low-cost&#xD;
      locally-made Venturi-based Non-invasive Positive Pressure Ventilator (NIPPV) device for&#xD;
      hypoxemic COVID-19 patients. The device administers Continuous Positive Airway Pressure&#xD;
      (CPAP) therapy using the jet-mixing or Venturi effect to increase the volume flow rate of&#xD;
      oxygenated air from a pressurized cylinder by entraining the atmospheric air. To provide CPAP&#xD;
      therapy, this high flow of oxygenated air is delivered to the patient via a low-cost&#xD;
      non-vented mask with a tight seal with a High-Efficiency Particulate Air (HEPA) filter&#xD;
      connected to the exhalation limb. The tight seal and HEPA filter ensures a minimal risk of&#xD;
      aerosol generation and thus the device can be used without a negative pressure room. The&#xD;
      system consists of the developed Venturi-based flow-generator, a standard 22mm breathing&#xD;
      tube, a standard Y-connector, a non-vented CPAP mask (e.g., snorkel mask, helmet), a HEPA&#xD;
      filter, and a Positive End Expiratory Pressure (PEEP) valve. The bench-top testing of the&#xD;
      device is done in the laboratories of BUET and was verified that the device performs within&#xD;
      the CPAP guidelines provided by the Medicines and Healthcare products Regulatory Agency&#xD;
      (MHRA), UK. This study aims to assess the safety of and efficacy of the device in three&#xD;
      different steps: (1) design validation, (2) clinical feasibility and (3) pilot clinical trial&#xD;
      for safety and efficacy evaluation. Only if the device successfully passes the parts 1 and 2,&#xD;
      the investigators will proceed to the final clinical trial in step 3. In this final step, the&#xD;
      investigators aim to conduct a randomized controlled trial (RCT) evaluating for&#xD;
      non-inferiority of the CPAP intervention compared to standard HFNO treatment. The number of&#xD;
      ventilator-free days will be used as the primary outcome for efficacy, while patient&#xD;
      recovery, death, or need of intubation and other adverse events will be used as secondary&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ventilator-free days</measure>
    <time_frame>10 days</time_frame>
    <description>The total number of days the patient was able to avoid being placed under a mechanical ventilator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery of the patient</measure>
    <time_frame>30 days</time_frame>
    <description>The event that the patient has recovered and released from the hospital within 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or need of intubation</measure>
    <time_frame>10 days</time_frame>
    <description>The event that the patient dies or requires to be placed under a mechanical ventilator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen toxicity or other adverse events</measure>
    <time_frame>10 days</time_frame>
    <description>Oxygen toxicity or other adverse event rating according to the CTCAE scale (1-5)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <condition>Hypoxemia</condition>
  <arm_group>
    <arm_group_label>High Flow Nasal Oxygen (HFNO) treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous positive airway pressure (CPAP) therapy using OxyJet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal Oxygen (HFNO) treatment</intervention_name>
    <description>Administration of High Flow Nasal Oxygen (HFNO) to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). Adjust flow-rate and FiO2 as per standard HFNO treatment protocol.</description>
    <arm_group_label>High Flow Nasal Oxygen (HFNO) treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure (CPAP) therapy using OxyJet</intervention_name>
    <description>Administer CPAP to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). CPAP initiated with FiO2 at 40% and a 10cm PEEP. Titrate PEEP to 15 cm if required. Deliver additional oxygen via secondary port if a higher FiO2 is required.</description>
    <arm_group_label>Continuous positive airway pressure (CPAP) therapy using OxyJet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Confirmed or suspected COVID-19 patient (by RT-PCR) having severe pneumonia and&#xD;
             hypoxemia (SpO2 ≤90%) who did not respond to standard oxygen therapy (non-rebreather&#xD;
             mask on 15L/min at 100% FiO2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severely hypoxemic patients (SpO2≤85%)&#xD;
&#xD;
          -  Patients with low respiratory drive or requiring cardiopulmonary resuscitation&#xD;
&#xD;
          -  Patients with contraindications for CPAP&#xD;
&#xD;
          -  Pregnant status&#xD;
&#xD;
          -  Age &gt; 60 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Taufiq Hasan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bangladesh University of Engineering and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Robed Amin, MBBS, FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dhaka Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Taufiq Hasan, PhD</last_name>
    <phone>+8801817579844</phone>
    <email>taufiq@bme.buet.ac.bd</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dhaka Medical College</name>
      <address>
        <city>Dhaka</city>
        <zip>1000</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Md. Khairul Islam, MBBS,MCPS,FCPS</last_name>
    </contact>
    <investigator>
      <last_name>Dr. Robed Amin, MBBS, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Md. Khairul Islam, MBBS, FCPS, MCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Forhad Uddin Hasan Chowdhury, MBBS, FCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Md. Mohiuddin Sharif, MBBS, MPA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

